ClinicalTrials.gg
CompletedNCT00814645AIR001-CS02Updated Feb 17, 2012

Dose-Finding, Safety, Pharmacodynamic Effect Study of Sodium Nitrite Inhalation Solution in Normal, Healthy Volunteers

A Phase 1 interventional study of Sodium Nitrite Inhalation Solution and Placebo and AIR001 Inhalation Solution (Expansion arm) in Pulmonary Arterial Hypertension, sponsored by Aires Pharmaceuticals, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2012-02-17.

Sponsored by Aires Pharmaceuticals, Inc. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
25
Allocation
Non-randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 312 studies in Pulmonary Arterial Hypertension with a site in United States — 38 open to participants now, 56 under way, 12 of them phase 3. Pulmonary Arterial Hypertension · United States.

Enrollment
157th of 253
25 · median 40
Started
2008
with 18 others
Phase 1
32 of 312
2 open now
Registered
53rd of 312
by date

Among the 312 studies in Pulmonary Arterial Hypertension with a site in United States, this one is the 157th largest by enrollment of the 253 interventional ones that give a count, is one of 19 that started in 2008, is one of 32 in phase 1, and was the 53rd registered.

Pulmonary Arterial Hypertension

700 studies on the registry are indexed under Pulmonary Arterial Hypertension; 140 are open to participants now.

Browse Pulmonary Arterial Hypertension studies →

Open to participants now

38 of the 312 studies in Pulmonary Arterial Hypertension with a site in United States are open now. Recruiting first, the newest first:

33 more — sign in →

All 38 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger; 18 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 312 studies in Pulmonary Arterial Hypertension with a site in United States, or all of them as a file.
02

Study summary

This study is designed to investigate the safety and tolerability of AIR001 Inhalation Solution when administered under conditions of hypoxia and to identify dose levels of drug resulting in a reduction in pulmonary arterial pressure under these hypoxic conditions.

03

Conditions studied

  • Pulmonary Arterial Hypertension
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Normal male and female volunteers
  • Age 18-55
  • Demonstrate a rise in pulmonary artery pressure to low inspired oxygen concentration (a normal response to breathing a low level of oxygen)

Exclusion criteria

Exclusion Criteria:

  • Significant medical illnesses
  • Risk factors for pulmonary hypertension
  • G6PD or Cytochrome B5 Reductase deficiencies
  • History of any form of altitude sickness
  • Current prescription or over the counter medication use
05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
25 participants (actual)

Study arms

  • Active comparator
    Dose level 1

    a single dose (5 mg sodium nitrite)of AIR001 Inhalation Solution administered by inhalation following nebulization

    Drug: Sodium Nitrite Inhalation Solution

  • Active comparator
    Dose level 2

    a single dose(15 mg sodium nitrite) of AIR001 Inhalation Solution administered by inhalation following nebulization

    Drug: Sodium Nitrite Inhalation Solution

  • Active comparator
    Dose level 3

    a single dose(45 mg sodium nitrite) of AIR001 Inhalation Solution administered by inhalation following nebulization

    Drug: Sodium Nitrite Inhalation Solution

  • Active comparator
    Dose level 4

    a single dose(113 mg sodium nitrite) of AIR001 Inhalation Solution administered by inhalation following nebulization

    Drug: Sodium Nitrite Inhalation Solution

  • Placebo comparator
    Expansion arm

    On Day 1, subjects will receive a single placebo-form dose of inhaled nebulized AIR001 Inhalation Solution (containing diluent and excipient solutions alone). On Day 2, the same subjects will receive a single administration of AIR001 Inhalation Solution at the minimum pharmacologically active and safe dose identified from dose levels 1-4. Subjects will be blinded to the treatment schema.

    Drug: Placebo and AIR001 Inhalation Solution (Expansion arm)

Interventions

  • DrugSodium Nitrite Inhalation Solution

    a single dose of AIR001 Inhalation Solution administered by inhalation following nebulization

    Also known as: AIR001 Inhalation Solution

  • DrugPlacebo and AIR001 Inhalation Solution (Expansion arm)

    On Day 1, subjects will receive a single placebo-form dose of inhaled nebulized AIR001 Inhalation Solution (containing diluent and excipient solutions alone). On Day 2, the same subjects will receive a single administration of AIR001 Inhalation Solution at the minimum pharmacologically active and safe dose identified from dose levels 1-4. Subjects will be blinded to the treatment schema.

    Also known as: AIR001 Inhalation Solution

06

What researchers measure

Primary outcomes

  1. The measurement of pulmonary arterial pressures by echocardiography.

    Time frame: Pretreatment and up to 2 hours post treatment

Secondary outcomes

  1. Plasma pharmacokinetics

    Time frame: Pretreatment to 8 hours post treatment

  2. Hematology, blood chemistry, coagulation and urinalysis, methemoglobin, oxygen saturation, electrocardiogram, troponin, and vital signs and adverse events.

    Time frame: Pretreatment, post treatment, and 24 hours post treatment

07

Study locations

1 site
  • DaVita Clinical Research
    Minneapolis, Minnesota 55404, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2008, a primary completion of Apr 2009 and a completion of Jun 2009. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 22, 2008
First posted
Dec 25, 2008
Start
Dec 2008
Primary completionActual
Apr 2009
CompletionActual
Jun 2009
Last update
Feb 17, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 17, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00814645
Lead sponsor
Aires Pharmaceuticals, Inc.
Responsible party
Sponsor
First posted
Dec 25, 2008
Start date
Dec 2008
Primary completion
Apr 2009
Completion
Jun 2009
Last update
Feb 17, 2012

Study contacts

Suzanne K Swan, M.D.
principal investigator · Davita Clinical Research

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion